Thesis
BPL-003's two Phase 3 pivotal trials test whether Phase 2b MADRS results replicate at registrational scale in TRD
BPL-003, a psilocybin analog, is in two FDA-endorsed Phase 3 pivotal studies targeting treatment-resistant depression patients who have failed prior antidepressants. The thesis turns on whether ReConnection-1 and ReConnection-2 both replicate the Phase 2b MADRS reduction with statistical significance at Week 4. The primary competitive risk is COMPASS Pathways' COMP360, a psilocybin therapy in its own Phase 3 program targeting the same TRD population on a similar timeline.
Focus
BPL-003 Phase 3 topline data readout
early 2029
Bull
A positive outcome would be statistically significant, clinically meaningful MADRS score reductions at Week 4 versus placebo in both pivotal trials, closely mirroring the Phase 2b effect sizes at the 8 mg dose. This would validate the registrational program, support NDA submission, and position BPL-003 as a potential first-in-class psilocybin-based therapy for TRD with a robust double-blind dataset backing it.
Bear
The most likely failure modes are a dilution of effect size at the larger sample sizes — particularly if the 0.3 mg active placebo comparator used in Phase 2b is replaced by an inert placebo that raises expectancy effects — or a failure to achieve statistical significance in one or both trials. Heterogeneity in the TRD patient population across expanded enrollment sites, or a high placebo response rate, could also obscure a true drug effect on the MADRS primary endpoint.
Unlock the full thesis for ATAI.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.